UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
March 14, 2008
Date of Report (Date of earliest event reported)
OSI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| | | | | |
| Delaware | | 0-15190 | | 13-3159796 |
| | | | | |
(State or other jurisdiction of
incorporation) | | (Commission
File Number) | | (I.R.S. Employer
Identification No.) |
41 Pinelawn Road
Melville, NY 11747(Address of principal executive offices)
(631) 962-2000(Registrant’s telephone number, including area code)
N/A(Former name or former address,
if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | |
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a- 12) |
| | |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On March 14, 2008, OSI Pharmaceuticals, Inc. (“OSI”) announced that it had reached a preliminary agreement to settle a class action lawsuit filed on or about December 16, 2004 against OSI, certain of its current and former executive officers and certain of its current and former members of its Board of Directors. A copy of OSI’s press release, dated March 14, 2008, is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
On March 18, 2008, OSI announced that the decision of the European Patent Office to revoke one of OSI’s dipeptidyl peptidase IV patents, EP0896538, was upheld on appeal. A copy of OSI’s press release, dated March 18, 2008, is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
| | |
| Item 9.01. | | Financial Statements and Exhibits. |
| | | |
| Exhibit No. | | Description |
| | | |
| 99.1 | | Press Release dated March 14, 2008. |
| 99.2 | | Press Release dated March 18, 2008. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| Date: March 26, 2008 | OSI PHARMACEUTICALS, INC.
| |
| | By: | /s/ Barbara A. Wood | |
| | | Barbara A. Wood | |
| | | Senior Vice President, General Counsel and Secretary | |
| |
-2-
EXHIBIT INDEX
| | | |
| Exhibit No. | | Description |
| | | |
| 99.1 | | Press Release dated March 14, 2008. |
| 99.2 | | Press Release dated March 18, 2008. |
-3-
